Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -269.0%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $682157 | $1M | $4M | $1M | $2M | $4M | $4M | $2M | $2M | $3M | $2M |
| Enterprise Value | $875157 | $1M | $3M | $-25113 | $-445651 | $1M | $264101 | $-2693849 | $-1031064 | $-597178 | $139027 |
| P/E Ratio → | -0.10 | — | — | — | — | 9.89 | — | — | 0.75 | — | — |
| P/S Ratio | — | — | 7.92 | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.66 | 0.62 | 0.41 | 0.80 | 0.62 | 0.25 | 0.27 | 0.74 | 0.80 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 7.41 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 0.7% | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | -481.6% | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | -227.7% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -269.0% | -269.0% | -26.8% | -0.1% | -28.9% | 7.5% | -11.8% | -17.6% | 50.0% | -24.8% | -67.2% |
| ROA | -159.9% | -159.9% | -18.7% | -0.1% | -25.0% | 6.6% | -11.4% | -17.1% | 39.4% | -16.3% | -61.0% |
| ROIC | -49.3% | -49.3% | -54.1% | -42.1% | -30.9% | -31.0% | -27.6% | -16.6% | -22.0% | -187.3% | -221.0% |
| ROCE | -55.4% | -55.4% | -50.7% | -24.6% | -16.9% | -16.3% | -14.3% | -11.0% | -10.9% | -27.8% | -67.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.03 | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.04 | -0.63 | -0.52 | -0.56 | -0.58 | -0.64 | -0.39 | -0.91 | -0.75 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -107.43 | -107.43 | -13.13 | -191.30 | -80.01 | -49.10 | -55.77 | -29.03 | -113.29 | -155.75 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.40 | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 | 8.35 |
| Quick Ratio | 0.40 | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.40 | 7.95 |
| Cash Ratio | 0.34 | 0.34 | 0.52 | 9.74 | 19.90 | 26.52 | 23.79 | 29.00 | 32.10 | 20.31 | 7.37 |
| Asset Turnover | — | — | 0.05 | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 80.12 | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 10.1% | — | — | 134.1% | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $440101 | $440101 | $340566 | $340568 | $384717 | $321378 | $321378 | $321378 | $293867 | $171272 |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XTLB stock.
XTL Biopharmaceuticals Ltd.'s current P/E ratio is -0.1x. The historical average is 3.6x.
XTL Biopharmaceuticals Ltd.'s return on equity (ROE) is -269.0%. The historical average is -44.2%.
Based on historical data, XTL Biopharmaceuticals Ltd. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Imminent liquidity and insolvency
Distress Discount Masks Asset Value
Based on reported figures, XTLB trades at a price-to-sales ratio of 0.58, which appears to reflect extreme market skepticism regarding the company's ability to successfully commercialize its hCDR1 pipeline asset rather than a fundamental assessment of its long-term intellectual property potential within the autoimmune therapeutic market.
The current valuation multiples suggest that the market has largely written off the company's clinical prospects, pricing the equity near liquidation value. Investors should interpret this low P/S ratio as a reflection of the binary risk inherent in the firm's stalled R&D pipeline rather than a value-based entry point.
Liquidity Constraints Threaten Operational Continuity
According to the 2024Q4 balance sheet, the company's current ratio has deteriorated to 0.61, indicating that XTLB lacks sufficient liquid assets to cover its short-term liabilities, a precarious position that warrants immediate concern regarding the firm's ability to sustain operations without significant external capital injections.
The rapid decline in the current ratio from historical highs suggests that the company is consuming its remaining cash reserves at an unsustainable rate. This liquidity profile implies that the firm is highly vulnerable to even minor operational disruptions or delays in securing additional funding.
Negative Returns Reflect Capital Destruction
As reported in financial statements, XTLB's ROIC has consistently remained in negative territory, reaching -11.9% in 2024Q4, which highlights the company's inability to generate productive returns on invested capital while its primary clinical assets remain in the pre-commercial development phase without a clear path to monetization.
The persistent negative ROIC trend suggests that the capital allocated to R&D and administrative overhead is not currently creating economic value. This pattern of capital destruction is typical for early-stage biotech firms that have yet to achieve the clinical milestones necessary to justify their historical expenditure levels.
Misapplication of Traditional Valuation Metrics
Analysts frequently misapply the price-to-earnings ratio to XTLB, which is fundamentally flawed given the company's lack of recurring revenue and persistent net losses, thereby obscuring the true nature of the firm's financial risk and its reliance on speculative capital market funding for survival.
Using P/E ratios for a pre-revenue biotech entity ignores the reality that the company's value is derived entirely from the optionality of its clinical pipeline. Investors should instead focus on cash runway and the probability-weighted net present value of the hCDR1 asset to better assess the firm's actual risk-reward profile.